Evidence map›Paper›PMID 24292672›Full record

ArticleOncogene2014

Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein.

J Zhong, R-X Cao, J-H Liu, Y-B Liu, J Wang, L-P Liu, Y-J Chen, J Yang, Q-H Zhang, Y Wu and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. The Role of Protein Arginine Methyltransferases in DNA Damage Response.International journal of molecular sciences · 2022
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

J ZhongInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
R-X Cao1] Institute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China [2] Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, PR China.
J-H Liu1] Institute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China [2] Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, PR China.
Y-B LiuInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
J WangInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
L-P LiuInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
Y-J ChenInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
J Yang1] Institute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China [2] Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, PR China.
Q-H ZhangInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
Y WuInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
W-J DingInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
T Hong1] Institute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China [2] Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, PR China.
X-H Xiao1] Institute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China [2] Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, PR China.
X-Y ZuInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
G-B WenInstitute of Clinical Medicine, First Affiliated Hospital of University of South China, Hengyang, PR China.
First Affiliated Hospital of University of South China · CNUniversity of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human protein arginine N-methyltransferase 2 (PRMT2, HRMT1L1) is a protein that belongs to the arginine methyltransferase family, and it has diverse roles in transcriptional regulation through different mechanisms depending on its binding partners. In this study, we provide evidences for the negative effect of PRMT2 on breast cancer cell proliferation in vitro and in vivo. Morever, cyclin D1, one of the key modulators of cell cycle, was found to be downregulated by PRMT2, and PRMT2 was further shown to suppress the estrogen receptor α-binding affinity to the activator protein-1 (AP-1) site in cyclin D1 promoter through indirect binding with AP-1 site, resulting in the inhibition of cyclin D1 promoter activity in MCF-7 cells. Furthermore, a positive correlation between the expression of PRMT2 and cyclin D1 was confirmed in the breast cancer tissues by using tissue microarray assay. In addition, PRMT2 was found to show a high absent percentage in breast caner cell nuclei and the nuclear loss ratio of PRMT2 was demonstrated to positively correlate with cyclin D1 expression and the increasing tumor grade of invasive ductal carcinoma. Those results offer an essential insight into the effect of PRMT2 on breast carcinogenesis, and PRMT2 nuclear loss might be an important biological marker for the diagnosis of breast cancer.

Indexed as

AdultAgedAnimalsBiomarkers, TumorBlotting, WesternBreast NeoplasmsCarcinoma, Ductal, BreastCell Line, TumorCell NucleusCyclin D1FemaleGene Expression Regulation, NeoplasticHeterograftsHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsBiomarkers, TumorCCND1 protein, humanCyclin D1Intracellular Signaling Peptides and ProteinsMicroRNAsPRMT2 protein, humanProtein-Arginine N-Methyltransferases

Identifiers

PMID24292672
OpenAlexW2034070474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.